10142109Building a Sustainable Platform for rAAV Gene Therapy ManufacturingActiveCollaborative R&DInnovate UKThis project is focused on advancing **sustainable medicines manufacturing** by developing a cutting-edge **stable cell line** system to improve the production of adeno-associated virus (AAV), a key component in gene therapies. Current AAV production methods are costly and inefficient, particularly when scaling up to meet commercial demand. Our solution aims to create a reliable and **scalable** platform that will significantly increase production yields while reducing costs, making gene therapies more accessible and affordable for patients. A central goal of this project is to enhance **productivity** by streamlining the AAV production process. Current methods often suffer from variability in output and require significant resources. Our stable cell line system will address these inefficiencies, enabling **high-volume, consistent production** while reducing the time, labor, and materials required. This will lower the cost per dose, which is essential for the broader adoption of gene therapies. By improving **resource efficiency**, the technology ensures that manufacturers can produce more output with fewer inputs, making the production process both more productive and cost-effective. Furthermore, the system will contribute to more **sustainable manufacturing** practices by optimizing resource use and minimizing waste. The stable cell line platform will allow manufacturers to meet **regulatory standards** with greater ease, ensuring consistent production quality even at a larger commercial scale. This consistency is vital for the safe and effective production of gene therapies, ensuring that patients receive high-quality treatments. In addition to its impact on productivity and sustainability, the project will foster broader collaboration within the **gene therapy industry**. By creating a platform that can be easily adopted across the sector, we aim to support partnerships between manufacturers, researchers, and healthcare providers. These collaborations will enhance manufacturing capabilities and increase access to innovative treatments. Overall, this project has the potential to transform AAV manufacturing by significantly improving **productivity**, **scalability**, and **sustainability**, helping to make gene therapies more affordable and widely available.